{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:15:15Z","timestamp":1785698115074,"version":"3.56.0"},"reference-count":9,"publisher":"BMJ","issue":"12","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,12,4]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p>We present a case of a 34-year-old man with long-term diagnosis of eosinophilic oesophagitis (EoE) who did not achieve control of disease after multiple therapies including topical and systemic steroids, immune modulators and biologics. Initial endoscopic findings showed signs of active eosinophilic oesophagitis and biopsies were significant for up to 100 eosinophils per high power field during his various treatments. There was a significant improvement in the appearance of the oesophagus as well as the least number of eosinophils found in oesophagus biopsies after 3\u2009months of treatment with tofacitinib. There are no cases of EoE treated with tofacitinib. Tofacitinib should be considered for the treatment of eosinophilic oesophagitis given its evolving role as an immunosuppressive agent.<\/jats:p>","DOI":"10.1136\/bcr-2019-232558","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T04:55:26Z","timestamp":1576126526000},"page":"e232558","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib"],"prefix":"10.1136","volume":"12","author":[{"given":"Lybil Briscia","family":"Mendoza Alvarez","sequence":"first","affiliation":[{"name":"Pediatric Gastroenterology, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Liu","sequence":"additional","affiliation":[{"name":"Pathology, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Glover","sequence":"additional","affiliation":[{"name":"Gastroenterology, University of Mississippi Medical Center, Jackson, Mississippi, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,12,11]]},"reference":[{"key":"2025082710100534000_12.12.e232558.1","doi-asserted-by":"crossref","DOI":"10.1007\/s11894-018-0633-x","article-title":"Speculation as to why the frequency of eosinophilic esophagitis is increasing","volume":"20","author":"Spechler","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"key":"2025082710100534000_12.12.e232558.2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11938-018-0167-1","article-title":"New developments in the diagnosis, therapy, and monitoring of eosinophilic esophagitis","volume":"16","author":"Patel","year":"2018","journal-title":"Curr Treat Options Gastroenterol"},{"key":"2025082710100534000_12.12.e232558.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4482","article-title":"Eosinophilic esophagitis: update on management and controversies","volume":"359","author":"Chen","year":"2017","journal-title":"BMJ"},{"key":"2025082710100534000_12.12.e232558.4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/bcpt.12164","article-title":"Therapeutic targeting of the JAK\/STAT pathway","volume":"114","author":"Aittom\u00e4ki","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025082710100534000_12.12.e232558.5","first-page":"156","article-title":"Medical and dietary management of eosinophilic esophagitis. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, &amp","volume":"121","author":"Nhu","year":"2018","journal-title":"Immunology"},{"key":"2025082710100534000_12.12.e232558.6","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the agree conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"2025082710100534000_12.12.e232558.7","doi-asserted-by":"crossref","unstructured":"Carr S , Chan ES , Watson W . Eosinophilic esophagitis. Allergy Asthma Clin Immunol 2018;14.doi:10.1186\/s13223-018-0287-0","DOI":"10.1186\/s13223-018-0287-0"},{"key":"2025082710100534000_12.12.e232558.8","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2018.00247","article-title":"Eosinophilic esophagitis: review and update","volume":"5","author":"Gomez Torrijos","year":"2018","journal-title":"Front Med"},{"key":"2025082710100534000_12.12.e232558.9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157376","article-title":"JAK-STAT6 pathway inhibitors block eotaxin-3 secretion by epithelial cells and fibroblasts from esophageal eosinophilia patients: promising agents to improve inflammation and prevent fibrosis in EoE","volume":"11","author":"Cheng","year":"2016","journal-title":"PLoS One"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2019-232558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T17:10:15Z","timestamp":1756314615000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2019-232558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":9,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,11]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bcr-2019-232558"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2019-232558","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}